A genus of ascomycete yeasts that includes both a proven therapeutic probiotic (S. boulardii) and species associated with disease states (S. cerevisiae enriched in CRC mycobiome). This dual nature — commensal/probiotic versus disease-associated — parallels the bacterial genus ruminococcus and highlights the importance of species-level resolution in mycobiome studies.
S. boulardii -- Therapeutic Probiotic
- The best-characterized fungal probiotic, with demonstrated efficacy in:
- C. difficile infection: reduces recurrence by 50-60% when combined with antibiotics (McFarland 2006 Am J Gastroenterol; Surawicz et al. 2000 Clin Infect Dis); inhibits toxin A/B binding to colonocytes and degrades toxin receptor sites (Castagliuolo et al. 1999 Infect Immun).
- Anti-inflammatory effects: secretes anti-inflammatory factors that inhibit NF-kB signaling and reduce IL-8 and TNF-alpha production in intestinal epithelial cells (Sougioultzis et al. 2006 BBRC).
- Barrier protection: upregulates tight junction proteins and secretory IgA production (Czerucka et al. 2007 Aliment Pharmacol Ther).
- Antibiotic-associated diarrhea: reduces incidence by approximately 50% across meta-analyses (Szajewska & Kołodziej 2015 Aliment Pharmacol Ther; Hempel et al. 2012 JAMA).
- Multiple sclerosis adjunctive use: evaluated as an adjunctive microbiome-targeted intervention in RCT [1].
- Unlike bacterial probiotics, S. boulardii is inherently resistant to all antibacterial antibiotics, making it uniquely suited for co-administration during antibiotic therapy (Czerucka et al. 2007 Aliment Pharmacol Ther).
- Produces 54-kDa serine protease that degrades C. difficile toxin A and its intestinal receptor (Castagliuolo et al. 1996 Infect Immun; Castagliuolo et al. 1999 Infect Immun).
S. cerevisiae in Disease
Colorectal Cancer Mycobiome
- S. cerevisiae is enriched in the CRC mycobiome in multiple cohorts. Saccharomycetaceae showed significant reductions in CRC in some studies, suggesting context-dependent effects [2].
- Interacts with bacterial communities: Saccharomyces abundance positively correlated with Bifidobacterium, Roseburia, and Ruminococcus in IBD patients [2].
Cardiometabolic Disease
- Saccharomyces enriched in HTN+CKD comorbidity patients; positively associated with IFN-gamma, IL-4, and eGFR [3].
- Present in hypertensive cohorts (8.46% of fungal community in HTN vs lower in normotensive controls) [4].
- S. boulardii supplementation failed to improve cardiac function in the GutHeart trial for heart failure (Awoyemi et al. 2021 eBioMedicine — GutHeart trial).
Autism Spectrum Disorder
- Saccharomyces abundance altered in gut mycobiome of ASD children, part of the broader fungal dysbiosis profile in the condition [5].
CRC Mycobiome-Bacteriome Integration
- Combined 16S and ITS profiling in Chinese CRC/adenoma cohorts places Saccharomyces within the fungal signature alongside key bacterial CRC biomarkers [6].
Crohn's Disease and ASCA
- Anti-Saccharomyces cerevisiae antibodies (ASCA) are a well-established serological marker for Crohn's disease, suggesting immune sensitization to this yeast in the inflamed gut (Main et al. 1988 BMJ; Quinton et al. 1998 Gut).
- ASCA positivity distinguishes Crohn's from UC (sensitivity ~55%, specificity ~90%) and is associated with more aggressive disease phenotype including stricturing and penetrating complications (Dubinsky et al. 2006 Inflamm Bowel Dis).
Metal Biosorption
- Saccharomyces species have significant metal biosorption capacity, binding heavy metals to cell wall components (mannoproteins, glucans, chitin) (Wang & Chen 2006 Biotechnol Adv).
- S. cerevisiae cell walls bind cadmium, lead, copper, zinc, and chromium from solution, a property exploited in industrial bioremediation (Wang & Chen 2006 Biotechnol Adv; Machado et al. 2010 J Hazard Mater).
- In the gut context, dietary or supplemental yeast may reduce bioavailable metal concentrations, potentially mitigating metal-induced dysbiosis.
- zinc-dependent alcohol dehydrogenase and Cu/Zn-superoxide dismutase are key metalloenzymes in Saccharomyces biology.
Key Metabolites
- Ethanol — primary fermentation product of S. cerevisiae; small amounts produced in the gut may affect hepatic metabolism.
- Beta-glucans — cell wall polysaccharides that stimulate Dectin-1 immune receptor, upregulating tight junction proteins and modulating macrophage function [2].
- Proteases — S. boulardii secretes serine proteases that degrade bacterial toxins and pro-inflammatory signaling molecules.
- Short-chain fatty acids — indirect contribution via cross-kingdom metabolic interactions with SCFA-producing bacteria.
Key Sources
Connections
- clostridioides difficile — S. boulardii is a proven therapeutic against CDI recurrence
- colorectal cancer — S. cerevisiae enriched in CRC mycobiome; ASCA antibodies relevant
- crohns disease — ASCA antibodies as serological marker; immune sensitization to yeast
- cardiovascular disease — enriched in HTN+CKD; failed to improve heart failure in GutHeart trial
- cadmium — cell wall biosorption capacity for Cd and other heavy metals
- lead — metal biosorption may reduce bioavailable Pb in the gut
- zinc — Zn-dependent enzymes; cell wall Zn-binding capacity
- copper — Cu/Zn-SOD for oxidative stress defense
- dysbiosis — S. boulardii counters dysbiosis; S. cerevisiae may signal disease states
- inflammation — S. boulardii anti-inflammatory (NF-kB inhibition); beta-glucans immunomodulatory
- gut metal microbiome — metal biosorption capacity links fungal biology to metal homeostasis
- roseburia — positive correlation in IBD mycobiome-bacteriome interactions